Literature DB >> 3261245

Interleukin 4 instructs uncommitted B lymphocytes to switch to IgG1 and IgE.

S Bergstedt-Lindqvist1, H B Moon, U Persson, G Möller, C Heusser, E Severinson.   

Abstract

Mouse interleukin 4 (IL 4) is a T cell-produced lymphokine with multiple effects on different cells types of the hematopoietic lineages. IL 4 has pronounced effects on B lymphocytes, where it induces high levels of IgG1 and IgE secretion in lipopolysaccharide-stimulated cultures that would otherwise secrete predominantly IgG3 and IgG2b (of the non-IgM isotypes). An important question is how IL 4 exerts its effect. Two main possibilities exist: (a) IL 4 instructs uncommitted B lymphocytes to IgG1 and IgE production; (b) IL 4 selects and expands an already precommitted B cell. In this study we show, by the use of limiting dilution analysis, that IL 4 dramatically increases the precursor frequency of IgG1 and IgE-secreting cells with no significant effect on the clone size, clearly suggesting that IL 4 instructs uncommitted B cells to switch to IgG1 and IgE. The fraction of total Ig precursors that can switch to the two isotypes is furthermore high. The high precursor frequency for IgE obtained in the presence of IL 4 further demonstrates that IL 4 is an important modulator of IgE responses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261245     DOI: 10.1002/eji.1830180716

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

1.  Abrogation of lung inflammation in sensitized Stat6-deficient mice is dependent on the allergen inhalation procedure.

Authors:  A Trifilieff; A El-Hasim; R Corteling; C E Owen
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Nerve growth factor induces growth and differentiation of human B lymphocytes.

Authors:  U Otten; P Ehrhard; R Peck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  Qualitative difference of anti-DNA antibody-producing cell precursors in the pre-immune B cell repertoire between normal and lupus-prone mice.

Authors:  K Iwai; T Tsubata; Y Katsura; S Kumagai; H Imura
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

4.  Host defense against cholera toxin is strongly CD4+ T cell dependent.

Authors:  E Hörnqvist; T J Goldschmidt; R Holmdahl; N Lycke
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 5.  Molecular effects of cholera toxin on isotype differentiation.

Authors:  N Lycke; E Severinson; W Strober
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

6.  Alterations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients.

Authors:  J M Ferrer; J Iglesias; M Hernández; N Matamoros
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

Review 7.  Cellular signalling mechanisms in B lymphocytes.

Authors:  W Cushley; M M Harnett
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

Review 8.  Can anti-IgE be used to treat allergy?

Authors:  F M Davis; L A Gossett; K L Pinkston; R S Liou; L K Sun; Y W Kim; N T Chang; T W Chang; K Wagner; J Bews
Journal:  Springer Semin Immunopathol       Date:  1993

Review 9.  Modeling TH 2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma.

Authors:  Paul S Foster; Steven Maltby; Helene F Rosenberg; Hock L Tay; Simon P Hogan; Adam M Collison; Ming Yang; Gerard E Kaiko; Philip M Hansbro; Rakesh K Kumar; Joerg Mattes
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

10.  Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation.

Authors:  Daniela Cihakova; Jobert G Barin; Marina Afanasyeva; Miho Kimura; DeLisa Fairweather; Michael Berg; Monica V Talor; G Christian Baldeviano; Sylvia Frisancho; Kathleen Gabrielson; Djahida Bedja; Noel R Rose
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.